Published in Am J Pharm Educ on October 14, 2013
Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy (2014) 0.96
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy (2014) 0.88
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy (2016) 0.78
Challenges to integrating pharmacogenetic testing into medication therapy management. J Manag Care Spec Pharm (2015) 0.77
AdvoCaring: A Cocurricular Program to Provide Advocacy and Caring to Underserved Populations in Baltimore. Am J Pharm Educ (2016) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med (2011) 4.05
Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther (2012) 3.91
Updated guidelines for manuscripts describing instructional design and assessment: the IDEAS format. Am J Pharm Educ (2009) 3.02
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am J Pharm Educ (2010) 1.77
Recommendations of core competencies in genetics essential for all health professionals. Genet Med (2001) 1.65
Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ (2011) 1.62
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther (2012) 1.40
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther (2012) 1.31
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09
A required course in human genomics, pharmacogenomics, and bioinformatics. Am J Pharm Educ (2006) 1.08
Development and evaluation of a pharmacogenomics educational program for pharmacists. Am J Pharm Educ (2013) 1.06
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics (2005) 0.95
Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics (2012) 0.89
Assessment of healthcare students' views on pharmacogenomics at the University of Minnesota. Pharmacogenomics (2012) 0.85
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54
Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm (2010) 1.42
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Factors that influence prescribing decisions. Ann Pharmacother (2004) 1.24
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
PARP and RIP 1 are required for autophagy induced by 11'-deoxyverticillin A, which precedes caspase-dependent apoptosis. Autophagy (2011) 1.08
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
Providing newborn resuscitation at the mother's bedside: assessing the safety, usability and acceptability of a mobile trolley. BMC Pediatr (2014) 1.06
Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol (2007) 1.04
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy (2011) 1.03
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy (2010) 0.96
Anticoagulation management services: entering a new era. Pharmacotherapy (2010) 0.92
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90
Predictors of unstable anticoagulation in African Americans. J Thromb Thrombolysis (2008) 0.90
Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm (2008) 0.89
Stakeholder views on pharmacogenomic testing. Pharmacotherapy (2013) 0.88
The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol (2009) 0.88
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy (2014) 0.87
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ (2013) 0.85
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy (2011) 0.85
E-prescribing: history, issues, and potentials. Online J Public Health Inform (2012) 0.85
Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. Ann Pharmacother (2008) 0.84
Cardiovascular pharmacogenomics. Exp Physiol (2005) 0.84
Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail (2013) 0.84
Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. Pharmacotherapy (2005) 0.83
Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism. Curr Med Res Opin (2011) 0.82
Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest (2006) 0.82
Clopidogrel and proton pump inhibitors: between a rock and a hard place. Pharmacotherapy (2010) 0.81
Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy (2007) 0.81
A clinician's guide to perioperative bridging for patients on oral anticoagulation. J Pharm Pract (2010) 0.81
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res (2012) 0.80
Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. Ann Pharmacother (2009) 0.80
Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit (2011) 0.79
Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures. Am J Health Syst Pharm (2011) 0.79
Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm (2002) 0.79
Impact of prescribing guidelines for inpatient anticoagulation. Ann Pharmacother (2004) 0.79
Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm (2007) 0.79
Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home. Am J Geriatr Pharmacother (2012) 0.79
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost (2013) 0.78
Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. Curr Med Res Opin (2014) 0.78
Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother (2006) 0.78
Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. Semin Thromb Hemost (2004) 0.78
Incidence of venous thromboembolism in nursing home residents. J Am Med Dir Assoc (2013) 0.77
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics (2015) 0.77
Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy (2011) 0.77
Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother (2005) 0.77
Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One (2013) 0.77
Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics? J Thromb Thrombolysis (2007) 0.77
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77
YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease. Curr Opin Investig Drugs (2010) 0.76
Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother (2005) 0.76
Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm (2015) 0.76
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clin Ther (2011) 0.76
All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost (2013) 0.76
Shifting paradigms in oral anticoagulation management. J Cardiovasc Pharmacol Ther (2004) 0.75
Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress. Future Cardiol (2015) 0.75
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics (2017) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
Uncertain times for oral anticoagulation therapy. Am J Health Syst Pharm (2005) 0.75
Ximelagatran: an oral direct thrombin inhibitor. Ann Pharmacother (2004) 0.75
Cost is not a barrier to implementing clopidogrel pharmacogenetics. Pharmacotherapy (2012) 0.75
Key articles and guidelines in the primary prevention of ischemic stroke. Pharmacotherapy (2013) 0.75
beta-adrenergic receptor pharmacogenetics. Future Cardiol (2007) 0.75
Pyrosequencing of the CYP2C9 -1766T>C polymorphism as a means of detecting the CYP2C9*8 allele. Pharmacogenomics (2014) 0.75
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Curr Med Res Opin (2011) 0.75
Matrix Metalloproteinase Polymorphisms in Patients with Floppy Mitral Valve/Mitral Valve Prolapse (FMV/MVP) and FMV/MVP Syndrome. Cardiology (2017) 0.75
New approaches to reversing oral anticoagulant therapy. Introduction. Am J Health Syst Pharm (2013) 0.75
The evolving role of dabigatran etexilate in clinical practice. Expert Opin Pharmacother (2015) 0.75
Current and emerging treatment options for venous thrombosis: a case discussion. Am J Health Syst Pharm (2005) 0.75
Examining differences in weekly warfarin dose in patients with and without cancer. Ther Drug Monit (2007) 0.75
Pharmacogenomics in heart failure: individualizing therapy based on genotype. Future Cardiol (2006) 0.75
Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke. Cerebrovasc Dis (2009) 0.75
Key articles and guidelines in the acute management and secondary prevention of ischemic stroke. Pharmacotherapy (2013) 0.75
New treatment option for heart failure patients: eplerenone. J Cardiovasc Nurs (2004) 0.75
Personalized medicine in cardiology: the time for genotype-guided therapy is now. Future Cardiol (2013) 0.75